Looking over US stocks all week this week and some of last week, we’ve seen bad news. Unfortunately, economic decline in Greece along with China’s market crash are dragging US markets down as well. However, even in poor market conditions, there are opportunities to be taken advantage of. With that said, here are several opportunities in the biotech market to keep a close eye on…
Synergy Pharmaceuticals Is Waiting For Its Time To Shine
Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
Synergy Pharmaceuticals has been following a relatively interesting trend recently. After steep climbs a few weeks ago, the stock corrected, stalled out, climbed shortly and seems to be correcting again. Wow, that was a lot. Nonetheless, I think that all of this volatile movement isn’t really worth paying too much attention to. The reality is that Synergy Pharmaceuticals, like most stocks on the market today, is being slammed with negativity from Greece, China, potential oil declines, and more. Nonetheless, the company is waiting for its time to shine. As these issues come to a resolution, I’m expecting to see a massive breakout from the stock. The reality is that they climbed in the first place from positive study results; and plecanatide is in its second of 2 Phase 3 studies. Soon, it will be headed for FDA approval. So, there are several catalysts waiting in the wings. With that said, keep a close eye on this one. If you’re not already in, you may want to start looking for buying opportunities.
MannKind Corporation Is About To Launch Its Secret Weapon
MannKind Corporation (NASDAQ: MNKD)
I’ve been talking about this for quite some time now; and as it gets closer and closer, I’m becoming more and more excited. MannKind has caught a bit of flack about poor Afrezza sales. However, what needs to be remembered is the fact that Afrezza is still in its pre-launch phase, but not for long. MannKind’s Afrezza will be moving to the direct-to-consumer phase of marketing. This is likely to prove to be a catalyst as investors are waiting to see positive sales of the drug. The good news is that the D2C phase is just around the corner. So, I’m expecting to see gains relatively soon.
Prima Biomed’s Climb Couldn’t Sustain….For Now
Prima Biomed Sp ADR (NASDAQ: PBMD)
Prima Biomed had a decent climb yesterday after receiving positive scientific advice from the European Medicines Agency. The advice received helped with the development path for it’s lead product known as IMP321; an experimental drug designed to treat metastatic breast cancer. Unfortunately however, the stock simply couldn’t sustain the growth with all the bearish activity around the world dragging it down. Nonetheless, as the smoke clears, I’m expecting to see more gains out of PBMD. So, this is another one worth watching closely.
Gilead Sciences Will See Growth…Mark My Words!
Gilead Sciences, Inc. (NASDAQ: GILD)
What would a biotech opportunity post be without mentioning Gilead Sciences. I’ve talked about this quite a bit in the past, so I won’t go into much detail. Nonetheless, here’s why GILD is likely to see growth…
- Maintained market leadership position in the HCV and HIV treatment markets.
- Low P/E ratio; showing that the stock is incredibly under-valued at the moment…definitely one of the value investors!
- Strong management and team of doctors and scientists will push this forward.
Keeping those factors in mind, this is another that’s well worth watching for entrance opportunities.
Do You Know Of Any Others?
Do you know of any other biotech stocks that are presenting opportunities? If so, let us know in the comments below!